Levosimendan Amdipharm (Levosimendan)

Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium, which enhances myocardial contraction without raising intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation and reducing cardiac after‑load.

The dosing regimen for Levosimendan Amdipharm is determined by the prescribing clinician based on the patient’s clinical condition, severity of heart failure, and response to therapy. Specific infusion rates and duration are individualized and not publicly standardized.

Levosimendan’s safety profile in pregnancy and lactation has not been established. It is classified as having an unknown pregnancy category, and use is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike traditional inotropes that increase intracellular calcium, levosimendan sensitises troponin C to existing calcium, offering improved contractility with a lower risk of calcium‑mediated toxicity. It also provides vasodilation, which many pure inotropes lack, potentially reducing after‑load and improving overall cardiac efficiency.

Levosimendan Amdipharm should be stored at 2‑8 °C in a refrigerator. Keep the solution in its original container, protect it from light, and avoid freezing or shaking the vial to maintain product stability.

Levosimendan Amdipharm is given as an intravenous infusion. The preparation is added to a compatible infusion set and administered under continuous hemodynamic monitoring, typically in an intensive‑care or cardiac‑care unit.

Serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare allergic reactions such as anaphylaxis. Continuous monitoring of blood pressure, cardiac rhythm and ECG is essential during and after the infusion.

Levosimendan is contraindicated in patients with uncontrolled severe hypotension, known hypersensitivity to the drug, or those receiving other potent vasodilators that could precipitate dangerous blood‑pressure drops. Caution is also advised in severe hepatic impairment.